Under the strong call to reduce medical expenses, many people point their finger at the configuration of medical equipment . Dean of a public hospital in South China recently told reporters about the configuration of large hospital equipment. He admits that the fact that many hospitals are competing to buy new equipment is a large number of equipment under-employment, and the result is that high medical equipment costs are distributed to patients.
Recently, relevant state departments revealed that in the future, the allocation of new medical equipment in hospitals should be based on clinical practice, strictly control the configuration of scientific research equipment, and also promote regional equipment sharing. The forthcoming "Twelfth Five-Year Plan A Large Medical Equipment Configuration Plan" proposes that the national PET-CT configuration plan should be implemented step by step, with emphasis on supporting regional medical centers and allocation of blank areas.
The seemingly bad news has caused a lot of scented fund companies to pay attention. The state advocates regional resource sharing, which will inevitably promote the integration of different types of imaging technologies, and then form new technologies and new equipment. Another industry's explosive growth opportunities are brewing.
Growing troubles
It is reported that the country will strengthen the technical tracking and forward-looking management of new large-scale medical equipment, and strictly supervise and control the operation of surgical robots and equipment with high cost of consumables. In accordance with the principle of reasonable compensation for costs and non-profit, the price of medical services for large-scale medical equipment will be formulated and adjusted to reduce the burden of medical expenses for the people. The problem is that, like many emerging industries in the growth stage, there are many medical device manufacturers in China, but the overall scale is small and the homogenization competition is serious.
Some experts said that nearly 70% of the high-end medical market in China is divided. The medical equipment market such as nuclear magnetic, MR, CT, etc. is mainly concentrated in the hands of GE, Philips, etc., in the field of medical electronic products, 90% of ECG machines, 80% of medium and high-end The monitor and 90% of the high-end multi-channel physiological recorders are occupied by international brands. Many brands such as Medtronic, Canon, and Ruiyi have developed detailed plans for the Chinese market. Domestic brands have been freed from low-end value-added types such as massage appliances and blood pressure monitors.
Although the current total size of China's medical machinery industry is nearly 300 billion yuan, there are more than 14,000 related production enterprises, and the annual output value growth rate exceeds 20%. However, behind the glare data, the domestic medical device industry is weak overall. In this big cake, domestic brands only account for 30%. “Obviously, the medical device market is a technology, but from this level, domestic companies are not able to do so. This can be seen from the country’s policy orientation. Fund companies are also paying close attention to investment changes and opportunities in the medical device industry.†The person pointed out.
According to the information disclosed by listed companies, domestic medical equipment listed companies generally have better performance. The net profit growth of Wandong Medical, Tongce Medical and Xinhua Medical, which are funded by the fund, is not bad. From January to October 2012, China's medical machinery sector disclosed 9 cases of mergers and acquisitions, amounting to 8.37 billion yuan, an increase of 200%. It should not be overlooked that the US Medtronic Company completed the acquisition of Kanghui for US$816 million, followed by the purchase of 19% equity of Shenzhen Xianjian Technology Co., Ltd., and the purchase of two Chinese medical device companies within 20 days. The multinational company was “localizedâ€. The determination has intensified this competitive format.
A researcher from a fund company in Shenzhen believes that from the internal and external environment, the investment opportunities of medical equipment are more likely to be bred in the future. The large medical equipment market will have new development space in the future, but only if it has enough to cope with the domestic market internationally. The ability to compete.
Ketoconazole is an imidazole antifungal drug. Its mechanism of action is to inhibit the biosynthesis of ergosterol in fungal cell membrane, affect the permeability of cell membrane and inhibit its growth. Ketoconazole can be used for the treatment of superficial and deep fungal diseases, such as skin and nail ringworm, vaginal candidiasis, gastrointestinal fungal infections, and systemic infections caused by Candida albicans, coccoides, histoplasmosis, etc. The treatment of chronic and recurrent candidiasis vaginalis was ineffective by local treatment.
It is used to prevent and treat patients who are susceptible to fungal infection due to the reduction of immune function (heredity and caused by disease or drug).
Product Name: Ketoconazole Powder
Specification: 99%
Appearance: White powder
CF:C26H28Cl2N4O4
molecular weight : 531.431
CAS: 65277-42-1
Ketoconazole is an imidazole antifungal drug. Its mechanism of action is to inhibit the biosynthesis of ergosterol in fungal cell membrane, affect the permeability of cell membrane and inhibit its growth. Ketoconazole can be used for the treatment of superficial and deep fungal diseases, such as skin and nail ringworm, vaginal candidiasis, gastrointestinal fungal infections, and systemic infections caused by Candida albicans, coccoides, histoplasmosis, etc.
Why Choose us?
Product Recommended
Cisapride Capsule,Acepromazine Maleate,Ketoconazole Powder,Selenium Sulfide
Xi'an Tian Guangyuan Biotech Co., Ltd. , https://www.tgybiotech.com